From helping Shenzhou Aerospace and science and technology fight the epidemic, to responding to the implementation of the national strategic development plan for emerging industries and promoting the upgrading of intelligent manufacturing, as a leading enterprise in the industry, Qingdao Haier Biomedical Co.Ltd(688139) in recent years, while paying attention to its own sustainable operation, it has actively undertaken the national strategic tasks and fulfilled its social responsibilities, and embarked on a road to achieve high-quality development in the implementation of the national strategy.
Recently, the Qingdao Haier Biomedical Co.Ltd(688139) medical industrialization project, an investment project within the central budget supported by the national development and Reform Commission and the Ministry of industry and information technology, successfully passed the acceptance. The successful implementation of the project not only marks the company’s phased and significant achievements in responding to the implementation of national intelligent manufacturing upgrading and improving the level of biosafety high-end medical equipment, but also means that the implementation of the company’s life science and medical innovation digital scene ecological strategy has been fully promoted and guaranteed.
implement national policies to benefit people’s livelihood, and promote industrial upgrading with benchmarking intelligent Factory
Qingdao Haier Biomedical Co.Ltd(688139) medical industrialization project is an intelligent manufacturing innovation project supported by national core departments under the background of national strategies such as the decision of the State Council on accelerating the cultivation and development of strategic emerging industries and made in China 2025. Relying on Haier’s existing national industrial Internet platform, the project has built an intelligent factory integrating product R & D and design, intelligent manufacturing, production management, marketing and other links, and is committed to becoming the most competitive R & D and industrialization base of biosafety high-end medical devices and equipment in the world.
Based on the current situation of weak foundation and high development requirements of China’s biosafety industry, under the policy guidance and market demand, as the leader and deep cultivator of the biosafety industry of the Internet of things, Qingdao Haier Biomedical Co.Ltd(688139) undoubtedly becomes the only carrier for policy implementation and demand satisfaction. By building a benchmarking intelligent factory and forming a digital incubation platform, the company forms an ecological closed loop in the field of scientific and innovative technology research and development, high-end equipment manufacturing, scheme customization incubation, ecological interconnection co creation and channel network sales in the biosafety industry, shapes a new business form of “Chinese intelligent manufacturing” in the biosafety industry and promotes the overall upgrading of the industry.
In terms of effectiveness, the project not only promotes the implementation of national policies, benefits people’s livelihood and meets market demand, but also achieves win-win results for all stakeholders. Taking the digital blood safety solution incubated by the project as an example, it constructs a blood safety scene ecology including blood stations, hospitals and plasma collection stations, which can improve the blood utilization rate and save blood for the government; For blood stations, the regional blood management platform is used to realize the rational allocation of blood among regions; For patients, the waiting time is reduced and the treatment efficiency is improved.
In addition, the successful acceptance of the project has important promotion and reference significance for improving the overall manufacturing level of biosafety high-end equipment, promoting technological innovation and industrialization of scientific and technological achievements, promoting green development, optimizing product structure, and promoting the integration of informatization and industrialization. In the future, the project may serve as the benchmark of China’s first intelligent factory for biosafety high-end equipment, support the company’s business model to further transform and upgrade from product manufacturing and sales to “product + service” solutions, and further strengthen the competitiveness of the mainstream stage of international competition.
core technology diversified innovation, driven by digital industry platform for efficient development
With the maturity of Qingdao Haier Biomedical Co.Ltd(688139) medical industrialization project, while complying with the policy oriented market demand, its digital industry platform also brings sufficient support for Qingdao Haier Biomedical Co.Ltd(688139) itself to drive high-quality development and performance realization with science and innovation.
Since its completion, relying on the project, Qingdao Haier Biomedical Co.Ltd(688139) medical has integrated the key core technologies of biosafety with digital technology innovation such as Internet of things, big data, AI and 5g, and integrated them into the two scenes of medical innovation and life science. It has successfully incubated panoramic customized solutions such as smart blood network, smart vaccine network, smart cloud eye network, smart biological sample network and smart medicine network, and built a digital base of biosafety, Provide assistance for the company’s continued good development.
According to the latest disclosed annual report data, Qingdao Haier Biomedical Co.Ltd(688139) 2021’s performance continued high growth, with a revenue of 2.126 billion yuan, a year-on-year increase of 51.63%; The total profit was 961 million yuan, a year-on-year increase of 126.49%; The net profit attributable to the parent company was 845 million yuan, a year-on-year increase of 121.82%. Relying on the medical industrialization project, the company took the platform as the carrier and promoted the rapid replication and expansion of major scenes through digital upgrading and innovation. The four sectors of blood safety, drug and reagent safety, sample safety and vaccine safety developed rapidly, with an increase of 266.32%, 49.26%, 21.78% and 102.71% respectively.
It is worth mentioning that based on the continuous exploration and deep cultivation in the field of biosafety, the biosafety science and Innovation Industrial Park project invested and built by Qingdao Haier Biomedical Co.Ltd(688139) in 2021 was officially launched. Recently, Qingdao Haier Biomedical Co.Ltd(688139) safety science and Technology Innovation Industrial Park was selected into the list of major projects in Shandong Province in 2022. After completion, the industrial park will be mainly used for the construction of biosafety multi scenario schemes such as biological culture, biological centrifugal preparation, sample automation, biological low-temperature transport and the production base of corresponding products, including the technology R & D base, laboratory base, experience cloud data center of biosafety scenario scheme and other biosafety Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) incubation. At that time, the development of the company will have more yuan and stronger driving force to provide more sufficient guarantee for self height, quality and sustainable development.
